TopRad

TopRad was a biotechnology company focused on developing a novel class of drugs designed to sensitize tumors to radiation therapy. The company's lead research centered on small molecule inhibitors of DNA topoisomerase II, specifically targeting the interaction between this enzyme and ionizing radiation to enhance DNA damage in cancer cells. Founded by researchers from the University of Chicago, TopRad aimed to improve the efficacy of standard radiotherapy while minimizing damage to healthy tissue. The company's approach sought to overcome radiation resistance in various solid tumors, though it appears to have ceased independent operations or transitioned into other research entities.